Pfizer's Licensing Deal: Pfizer has entered a licensing agreement worth up to $2.1 billion with YaoPharma to develop an obesity pill, which includes an upfront payment of $150 million and potential milestone payments of up to $1.94 billion.
Drug Development and Competition: The drug targets the GLP-1 hormone, similar to Novo Nordisk's Wegovy, but is still in early development. Pfizer aims to enhance its obesity drug pipeline after previous setbacks and a recent acquisition of Metsera.
Clinical Trials and Future Plans: YaoPharma will conduct initial phase one trials, while Pfizer will oversee later development stages and plans to explore combining this treatment with its own GIP-targeting drug.
Market Potential: Analysts suggest that the weight loss drug market could reach approximately $100 billion by the 2030s, making Pfizer's entry into this space potentially lucrative.
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 62.230
Low
42.00
Averages
54.67
High
70.00
Current: 62.230
Low
42.00
Averages
54.67
High
70.00
Goldman Sachs
Buy
maintain
2026-01-22
New
Reason
Goldman Sachs
Price Target
AI Analysis
2026-01-22
New
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Novo Nordisk to DKK 436 from DKK 352 and keeps a Buy rating on the shares. The firm believes investor focus in the first half of 2026 will be the launch for Novo's Wegovy pill. The weight loss pill should contribute to positive earnings momentum in the near term, the analyst tells investors in a research note.
CICC
initiated
$73.50
2026-01-08
Reason
CICC
Price Target
$73.50
2026-01-08
initiated
Reason
CICC initiated coverage of Novo Nordisk with an Outperform rating and $73.50 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NVO
Unlock Now
Barclays
Equal Weight
downgrade
2026-01-06
Reason
Barclays
Price Target
2026-01-06
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Novo Nordisk to DKK 360 from DKK 375 and keeps an Equal Weight rating on the shares.
Raymond James
Martin Auster
Strong Buy
initiated
$38
2025-12-19
Reason
Raymond James
Martin Auster
Price Target
$38
2025-12-19
initiated
Strong Buy
Reason
Raymond James analyst Martin Auster initiated coverage of Septerna (SEPN) with a Strong Buy rating and $38 price target. Septerna's G protein-coupled receptor discovery platform has produced two lead programs, SEP-631 for chronic spontaneous urticaria and mast cell diseases and SEP-479 for hypoparathyroidism, with additional validation from a 2025 metabolic disease partnership with Novo Nordisk (NVO), the analyst tells investors in a research note. With cash runway into 2029 and key Phase 1 and clinic-entry milestones in 1H26, upcoming data could meaningfully de-risk the pipeline and drive valuation upside ahead of potential Phase 2 proof-of-concept readouts, the firm says.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
